MDACC Study No:2010-0188 ( NCT No: NCT01200342)
Title:Phase II Study of Genasense-Carboplatin-Paclitaxel-combination in Uveal Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:Carboplatin; Genasense; Paclitaxel
Study Status:Terminated
Study Description:The goal of this clinical research is to learn if the combination of Genasense
(oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic
uveal melanoma. The safety of this combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:Carboplatin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Genta Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults